Droxinavir
Names
IUPAC name
3-tert-butyl-1-[(2R,3S)-3-[(2S)-3,3-dimethyl-2-[2-(methylamino)acetamido]butyramido]-2-hydroxy-4-phenylbutyl-1-isopentylurea
Other names
SC 55389A
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
UNII
  • InChI=1S/C29H51N5O4/c1-19(2)15-22(26(37)34-29(6,7)8)31-17-23(35)21(16-20-13-11-10-12-14-20)32-27(38)25(28(3,4)5)33-24(36)18-30-9/h10-14,19,21-23,25,30-31,35H,15-18H2,1-9H3,(H,32,38)(H,33,36)(H,34,37)/t21-,22?,23+,25+/m0/s1 checkY
    Key: PLQLXAKSONXQOQ-XCZUPJPTSA-N checkY
  • CC(C)CC(C(=O)NC(C)(C)C)NCC(C(CC1=CC=CC=C1)NC(=O)C(C(C)(C)C)NC(=O)CNC)O
Properties
C29H51N5O4
Molar mass 533.75 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N (what is checkY☒N ?)

Droxinavir (also known as SC 55389A) was an experimental protease inhibitor researched by Pharmacia as a treatment for HIV infection. Its research and development was discontinued on March 06, 1995.[1]

References

  1. ^ "Drug Profile: Droxinavir". AdisInsight. Adis International Ltd, part of Springer Science+Business Media. Retrieved 23 November 2015.
Categories